Steven Shum - INVO Bioscience CEO Director
| INVODelisted Stock | USD 0.84 0.03 3.45% |
Insider
Steven Shum is CEO Director of INVO Bioscience
| Age | 53 |
| Phone | 978 878 9505 |
| Web | https://www.invobioscience.com |
INVO Bioscience Management Efficiency
The company has return on total asset (ROA) of (0.2657) % which means that it has lost $0.2657 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (143.5864) %, meaning that it created substantial loss on money invested by shareholders. INVO Bioscience's management efficiency ratios could be used to measure how well INVO Bioscience manages its routine affairs as well as how well it operates its assets and liabilities.INVO Bioscience currently holds 8.68 M in liabilities with Debt to Equity (D/E) ratio of 0.6, which is about average as compared to similar companies. INVO Bioscience has a current ratio of 1.95, which is within standard range for the sector. Note, when we think about INVO Bioscience's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| II MD | Entera Bio | 71 | |
| Avani Kanubaddi | Enveric Biosciences | 51 | |
| Ibrahim MD | Enveric Biosciences | 55 | |
| Chad MBA | NLS Pharmaceutics AG | N/A | |
| Robert Weingarten | Lixte Biotechnology Holdings | 72 | |
| John MD | Lixte Biotechnology Holdings | 87 | |
| Eric JD | Lixte Biotechnology Holdings | 45 | |
| MBA IV | Enveric Biosciences | 68 | |
| Li Li | CLPS Inc | 48 | |
| Rhon Galicha | CLPS Inc | N/A | |
| Hillel MBA | Entera Bio | 46 | |
| Xiao Yang | CLPS Inc | 60 | |
| Joseph Tucker | Enveric Biosciences | 55 | |
| Peter Facchini | Enveric Biosciences | 60 | |
| Sharon Keys | NLS Pharmaceutics AG | N/A | |
| Ming Lin | CLPS Inc | 60 | |
| Srustijeet Mishra | CLPS Inc | N/A | |
| Rui Yang | CLPS Inc | 41 | |
| James MD | Lixte Biotechnology Holdings | 77 | |
| iur LLM | NLS Pharmaceutics AG | 58 | |
| Miranda MBA | Entera Bio | 47 | |
Management Performance
| Return On Equity | -143.59 | |||
| Return On Asset | -0.27 |
INVO Bioscience Leadership Team
Elected by the shareholders, the INVO Bioscience's board of directors comprises two types of representatives: INVO Bioscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of INVO. The board's role is to monitor INVO Bioscience's management team and ensure that shareholders' interests are well served. INVO Bioscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, INVO Bioscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kevin MD, Medical Director | ||
| FACS FACOG, VP Integration | ||
| Bojan Mitrovic, Director US | ||
| Lori MarzilliKahler, VP Operations | ||
| Michael Campbell, COO Development | ||
| Terah Krigsvold, Controller | ||
| Chris Myer, Sr Americas | ||
| Steven Shum, CEO Director | ||
| Andrea Goren, Chief Officer | ||
| Robert Bowdring, Treasurer Secretary |
INVO Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is INVO Bioscience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -143.59 | |||
| Return On Asset | -0.27 | |||
| Profit Margin | (1.23) % | |||
| Operating Margin | (1.04) % | |||
| Current Valuation | 15.19 M | |||
| Shares Outstanding | 3.91 M | |||
| Shares Owned By Insiders | 0.60 % | |||
| Shares Owned By Institutions | 3.00 % | |||
| Number Of Shares Shorted | 1.95 K | |||
| Price To Book | 5.97 X |
Pair Trading with INVO Bioscience
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if INVO Bioscience position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in INVO Bioscience will appreciate offsetting losses from the drop in the long position's value.Moving against INVO Stock
| 0.58 | MCD | McDonalds Fiscal Year End 3rd of February 2025 | PairCorr |
| 0.58 | IBM | International Business Fiscal Year End 22nd of January 2025 | PairCorr |
| 0.49 | GE | GE Aerospace Fiscal Year End 28th of January 2025 | PairCorr |
| 0.41 | MMM | 3M Company Fiscal Year End 28th of January 2025 | PairCorr |
The ability to find closely correlated positions to INVO Bioscience could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace INVO Bioscience when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back INVO Bioscience - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling INVO Bioscience to buy it.
The correlation of INVO Bioscience is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as INVO Bioscience moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if INVO Bioscience moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for INVO Bioscience can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Other Consideration for investing in INVO Stock
If you are still planning to invest in INVO Bioscience check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the INVO Bioscience's history and understand the potential risks before investing.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |